Tegsedi (inotersen)

Jul 04, 2018

Inotersen Treatment for Patients With Hereditary Transthyretin Amyloidosis

Background: Hereditary transthyretin amyloidosis is caused by pathogenic single-nucleotide variants in the gene encoding transthyretin ( TTR) that induce…

Tegsedi™ to be Available on the NHS for hATTR Amyloidosis

Akcea Therapeutics UK Ltd., has announced that NICE has issued a positive Final Evaluation Document (FED) for Tegsedi(tm) (inotersen) for the treatment of stage 1…

ESC: Tafamidis Cuts Deaths, Admissions in TTR Cardiac Amyloidosis

FDA OKs Inotersen (Tegsedi) for Hereditary ATTR With Polyneuropathy

Inotersen: An Exciting Prospect for hATTR Amyloidosis Treatment

Subscribe to

Newsletter

Expert and Community Perspectives on Attruby®

In this special session, Dr. Barry Trachtenberg and members of the ATTR amyloidosis community came together to share medical insights and lived experiences related to Attruby™ (acoramidis). This expert-led discussion explores the clinical data, the patient perspective, and what lies ahead for those considering or currently taking Attruby.